- Home
- GNW vs EWTX Comparison
GNW vs EWTX Comparison
Compare GNW & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GNW | EWTX |
|---|---|---|
| Founded | 1871 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Life Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.5B |
| IPO Year | 2004 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GNW | EWTX |
|---|---|---|
| Price | $8.86 | $34.09 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | $10.50 | ★ $39.00 |
| AVG Volume (30 Days) | ★ 2.4M | 1.3M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $7,301,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $74.42 | ★ N/A |
| Revenue Growth | ★ 0.08 | N/A |
| 52 Week Low | $6.75 | $12.31 |
| 52 Week High | $9.45 | $40.77 |
Technical Indicators
Market Signals| Indicator | GNW | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 53.13 | 50.40 |
| Support Level | $8.01 | $28.27 |
| Resistance Level | $9.21 | $35.00 |
| Average True Range (ATR) | 0.18 | 2.20 |
| MACD | 0.01 | -0.22 |
| Stochastic Oscillator | 61.08 | 29.32 |
Price Performance
Historical ComparisonAbout GNW Genworth Financial Inc
Genworth Financial Inc is a diversified insurance holding company that provides various mortgage and life insurance products. The company has four main operating business segments: Enact, Closed Block segment, and Corporate and Other. The company's product portfolio includes various financial products such as traditional life insurance, mortgage insurance, fixed annuities, and variable annuities. The majority of the revenue is generated by the Enact segment. The company earns the maximum of its revenue in the United States.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.